INVESTORS.

Regulus aims to develop novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases.

Home Page Ticker
NASDAQRGLS
Press Releases.
March 12, 2024

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

March 12, 2024

Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney...

January 02, 2024

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

More press releases

Events.
Tuesday, March 12, 2024
8:30am - 9:30am EDT
Wednesday, November 29, 2023
10:25am EST
Wednesday, September 20, 2023
8:30am - 9:30am EDT

More events

upcoming event.
No events to display

more events

corporate presentation.
email alerts.

Sign up for email alerts to receive the latest financial information from Regulus Therapeutics Inc.

Sign Up

IR contact.

Phone: 858-202-6300
Email: ir@regulusrx.com

Contact Us